{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:57:56Z","timestamp":1788587876466,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["16\/162\/01"],"award-info":[{"award-number":["16\/162\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Irritable bowel syndrome (IBS) is a common functional bowel disorder that has a considerable impact on patient quality of life and substantial societal and health care resource costs. Current treatments are often ineffective. Tricyclic antidepressants have shown promise in secondary care populations but their effectiveness in a primary care setting remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ATLANTIS is a randomised, multi-centre, parallel-group, two-arm, double-blind, placebo-controlled trial of low-dose amitriptyline as a second-line treatment for IBS in primary care. Participants will be invited by letter, or recruited opportunistically, from general practices in three regions of England (West Yorkshire, Wessex, and West of England) and screened for eligibility. A total of 518 adult patients with IBS, who are symptomatic despite first-line therapies, will be randomised 1:1 to amitriptyline or identical placebo for 6\u00a0months. Treatment will commence at a dose of 10\u00a0mg (or one placebo tablet) daily at night, with dose titration up to a maximum of 30\u00a0mg at night, depending on side effects and response to treatment. Participant-reported assessments will be conducted at baseline and 3, 6, and 12\u00a0months post-randomisation. The primary objective is to determine the effectiveness of amitriptyline, compared with placebo, in improving participant-reported global symptoms of IBS at 6\u00a0months (using the IBS Severity Scoring System). Secondary outcomes include relief of IBS symptoms, effect on IBS-associated somatic symptoms (Patient Health Questionnaire-12), anxiety and depression (Hospital Anxiety and Depression Scale), ability to work and participate in other activities (Work and Social Adjustment Scale), acceptability and tolerability of treatment, self-reported health care use, health-related quality of life (EQ-5D-3L), and cost-effectiveness. A nested, qualitative study will explore patient and general practitioner experiences of treatments and trial participation, including acceptability, adherence, unanticipated effects, and implications for wider use of amitriptyline for IBS in primary care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Determining the clinical and cost-effectiveness of low-dose amitriptyline as a second-line treatment for IBS in primary care will provide robust evidence to inform management decisions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN48075063\">ISRCTN ISRCTN48075063<\/jats:ext-link>\n. Registered on 7th June 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06492-6","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:03:06Z","timestamp":1657278186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care"],"prefix":"10.1186","volume":"23","author":[{"given":"Sarah L.","family":"Alderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Wright-Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Farrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Loo","family":"Ow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Teasdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Howdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elspeth","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie","family":"Foy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ridd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity L.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chaddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Gibbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel","family":"Everitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"6492_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1572-0241.2007.01740.x","volume":"103","author":"AC Ford","year":"2008","unstructured":"Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229\u201339.","journal-title":"Am J Gastroenterol"},{"key":"6492_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","volume":"5","author":"P Oka","year":"2020","unstructured":"Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:908\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6492_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/00042737-199707000-00008","volume":"9","author":"WG Thompson","year":"1997","unstructured":"Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol. 1997;9:689\u201392.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"6492_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/00365520310004524","volume":"38","author":"F Pace","year":"2003","unstructured":"Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Bianchi Porro G, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38:1031\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"6492_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","volume":"113","author":"A Frandemark","year":"2018","unstructured":"Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113:1540\u20139.","journal-title":"Am J Gastroenterol"},{"key":"6492_CR6","doi-asserted-by":"publisher","first-page":"h701","DOI":"10.1136\/bmj.h701","volume":"350","author":"C Hookway","year":"2015","unstructured":"Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ. 2015;350:h701.","journal-title":"BMJ"},{"key":"6492_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/flgastro-2013-100426","volume":"5","author":"UN Shivaji","year":"2014","unstructured":"Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Front Gastroenterol. 2014;5:266\u201371.","journal-title":"Front Gastroenterol"},{"key":"6492_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","volume":"101","author":"L Chang","year":"2006","unstructured":"Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-surveillance marketing data. Am J Gastroenterol. 2006;101:1069\u201379.","journal-title":"Am J Gastroenterol"},{"key":"6492_CR9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.cgh.2019.07.007","volume":"18","author":"CJ Black","year":"2020","unstructured":"Black CJ, Burr NE, Ford AC. Relative efficacy of tegaserod in a systematic review and network meta-analysis of licensed therapies for irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2020;18:1238-9.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6492_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-7843.2005.pto_96696601.x","volume":"96","author":"SH Sindrup","year":"2005","unstructured":"Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96:399\u2013409.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6492_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.gastro.2015.04.020","volume":"149","author":"NJ Talley","year":"2015","unstructured":"Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multi-center, randomized, controlled study. Gastroenterol. 2015;149:340\u20139.","journal-title":"Gastroenterol"},{"key":"6492_CR12","doi-asserted-by":"publisher","first-page":"j603","DOI":"10.1136\/bmj.j603","volume":"356","author":"J Wong","year":"2017","unstructured":"Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017;356:j603.","journal-title":"BMJ"},{"key":"6492_CR13","doi-asserted-by":"crossref","unstructured":"Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;Issue 4.","DOI":"10.1002\/14651858.CD005454.pub2"},{"key":"6492_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2036.1994.tb00273.x","volume":"8","author":"DA Gorard","year":"1994","unstructured":"Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:159\u201366.","journal-title":"Aliment Pharmacol Ther"},{"key":"6492_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF02063948","volume":"40","author":"DA Gorard","year":"1995","unstructured":"Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 1995;40:86\u201395.","journal-title":"Dig Dis Sci"},{"key":"6492_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1017\/S1463423614000383","volume":"16","author":"UN Shivaji","year":"2014","unstructured":"Shivaji UN, Ford AC. Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. Prim Health Care Res Dev. 2014;16:263\u20139.","journal-title":"Prim Health Care Res Dev"},{"issue":"8","key":"6492_CR17","first-page":"CD003460","volume":"2011","author":"L Ruepert","year":"2011","unstructured":"Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460.","journal-title":"Cochrane Database Syst Rev"},{"key":"6492_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","volume":"114","author":"AC Ford","year":"2019","unstructured":"Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114:21\u201339.","journal-title":"Am J Gastroenterol"},{"key":"6492_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2468-1253(19)30324-3","volume":"5","author":"CJ Black","year":"2020","unstructured":"Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:117\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6492_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2036.2008.03633.x","volume":"27","author":"H Vahedi","year":"2008","unstructured":"Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:678\u201384.","journal-title":"Aliment Pharmacol Ther"},{"key":"6492_CR21","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.3390\/jcm9092933","volume":"9","author":"SJ Oh","year":"2020","unstructured":"Oh SJ, Takakura W, Rezaie A. Shortcomings of trials assessing antidepressants in the management of irritable bowel syndrome: a critical review. J Clin Med. 2020;9:2933.","journal-title":"J Clin Med"},{"issue":"7","key":"6492_CR22","first-page":"CD008013","volume":"2011","author":"A Kaminski","year":"2011","unstructured":"Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G. Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev. 2011;2011(7):CD008013.","journal-title":"Cochrane Database Syst Rev"},{"key":"6492_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395\u2013402.","journal-title":"Aliment Pharmacol Ther"},{"key":"6492_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0895-4356(03)00027-1","volume":"56","author":"S Muller-Lissner","year":"2003","unstructured":"Muller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, et al. Subject\u2019s Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol. 2003;56:310\u20136.","journal-title":"J Clin Epidemiol"},{"key":"6492_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258\u201366.","journal-title":"Psychosom Med"},{"key":"6492_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2036.2010.04402.x","volume":"32","author":"RC Spiller","year":"2010","unstructured":"Spiller RC, Humes DJ, Campbell E, Hastings M, Neal KR, Dukes GE, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 2010;32:811\u201320.","journal-title":"Aliment Pharmacol Ther"},{"key":"6492_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"6492_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1192\/bjp.180.5.461","volume":"180","author":"JC Mundt","year":"2002","unstructured":"Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461\u20134.","journal-title":"Br J Psychiatry"},{"key":"6492_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/bmj.38545.505764.06","volume":"331","author":"T Kennedy","year":"2005","unstructured":"Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005;331:435\u20137.","journal-title":"BMJ"},{"key":"6492_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1017\/S0033291709990195","volume":"40","author":"R Moss-Morris","year":"2010","unstructured":"Moss-Morris R, McAlpine L, Didsbury LP, Spence MJ. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med. 2010;40:85\u201394.","journal-title":"Psychol Med"},{"key":"6492_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1192\/bjp.bp.108.061960","volume":"195","author":"R Uher","year":"2009","unstructured":"Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195:202\u201310.","journal-title":"Br J Psychiatry"},{"key":"6492_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"Group E","year":"1990","unstructured":"Group E. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"6492_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1524-4733.2006.00086.x","volume":"9","author":"DM Bushnell","year":"2006","unstructured":"Bushnell DM, Martin ML, Ricci JF, Bracco A. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health. 2006;9:90\u20137.","journal-title":"Value Health"},{"key":"6492_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1472-6963-7-148","volume":"7","author":"C May","year":"2007","unstructured":"May C, Finch T, Mair F, Ballini L, Dowrick C, Eccles M, et al. Understanding the implementation of complex interventions in health care: the normalization process model. BMC Health Serv Res. 2007;7:148.","journal-title":"BMC Health Serv Res"},{"key":"6492_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10865-016-9782-2","volume":"39","author":"H Leventhal","year":"2016","unstructured":"Leventhal H, Phillips LA, Burns E. The common-sense model of self-regulation (CSM): a dynamic framework for understanding illness self-management. J Behav Med. 2016;39:935\u201346.","journal-title":"J Behav Med"},{"key":"6492_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjhp.12304","volume":"23","author":"JM Harvey","year":"2018","unstructured":"Harvey JM, Sibelli A, Chalder T, Everitt H, Moss-Morris R, Bishop FL. Desperately seeking a cure: treatment seeking and appraisal in irritable bowel syndrome. Br J Health Psychol. 2018;23:561\u201379.","journal-title":"Br J Health Psychol"},{"key":"6492_CR37","doi-asserted-by":"publisher","first-page":"e008622","DOI":"10.1136\/bmjopen-2015-008622","volume":"5","author":"H Everitt","year":"2015","unstructured":"Everitt H, Landau S, Little P, Bishop FL, McCrone P, O\u2019Reilly G, et al. Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults. BMJ Open. 2015;5:e008622.","journal-title":"BMJ Open"},{"key":"6492_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.12787","volume":"40","author":"G Sisson","year":"2014","unstructured":"Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome\u2013a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40:51\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"6492_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.homp.2014.05.001","volume":"103","author":"EJ Peckham","year":"2014","unstructured":"Peckham EJ, Relton C, Raw J, Walters C, Thomas K, Smith C, et al. Interim results of a randomised controlled trial of homeopathic treatment for irritable bowel syndrome. Homeopathy. 2014;103:172\u20137.","journal-title":"Homeopathy"},{"key":"6492_CR40","first-page":"1613","volume":"68","author":"HA Everitt","year":"2019","unstructured":"Everitt HA, Landau S, O\u2019Reilly G, Sibelli A, Hughes S, Windgassen S, et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019;68:1613\u201323.","journal-title":"Gut"},{"key":"6492_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/gutjnl-2018-318160","volume":"69","author":"CJ Black","year":"2020","unstructured":"Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: Systematic review and network meta-analysis. Gut. 2020;69:74\u201382.","journal-title":"Gut"},{"key":"6492_CR42","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","volume":"155","author":"CJ Black","year":"2018","unstructured":"Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterol. 2018;155:1753\u201363.","journal-title":"Gastroenterol"},{"key":"6492_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"6492_CR44","doi-asserted-by":"crossref","unstructured":"Corbin J, Strauss A. Basics of qualitative research (3rd ed.): techniques and procedures for developing grounded theory. Thousand Oaks, California;\u00a02008.","DOI":"10.4135\/9781452230153"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06492-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06492-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06492-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:10:19Z","timestamp":1657282219000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06492-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6492"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06492-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent will be obtained from participants prior to entry into the trial. The trial was reviewed and received ethical approval from Yorkshire & The Humber Research Ethics Committee on 5 August 2019 (19\/YH\/0150; Additional file ), the Medicines & Healthcare products Regulatory Agency (EudraCT: 2019\u2013000324-17), the Health Research Authority (IRAS project ID 252282), and local CCGs\/R&D departments for each participating site prior to entering patients into the trial. The study is sponsored by the University of Leeds.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No data on individual persons are used in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"552"}}